The Cardiacense medical watch was chosen to monitor the vital signs and medical condition of the Israeli astronaut, Eitan Stiva, during his stay in space
Cardiacense, a technology company in the field of digital health, and the Israel Institute of Space and Aviation Medicine were chosen to launch the medical wristwatch, developed by the company, into space. A watch for continuous remote monitoring of vital indicators, and detection of heart rhythm disturbances and deterioration in the medical condition of patients with chronic diseases. A clock with a precision level of stationary medical equipment in hospitals. Cardiacense and the Israel Institute of Space and Aviation Medicine report that the Israeli medical watch was chosen to monitor the vital signs and medical condition of the Israeli astronaut, Eitan Stiva, during his stay on the International Space Station as part of a rocket project.
Stiva is expected to take off into space this February as part of the Rakei project, on behalf of the Ramon Foundation and in cooperation with the Israel Space Agency. Sky Project is part of SpaceX's first private space mission. Cardiacsense's medical watch, which was chosen as one of the scientific developments that will accompany the mission, will monitor Stiva's vital signs and medical condition throughout the mission, starting from the time of launch and during his time on the space station. Cardiacense's medical watch, which has already received the approval of the European and Israeli medical regulations, will be launched for commercial use in the world during the next quarter.
"This is a first-of-its-kind project made possible thanks to the unique and innovative technology of the Cardiacense company and is an expression of the project managers' confidence in the company's medical watch and its capabilities," said Eldad Shemesh, founder and CEO of Cardiacense. "We are proud to take part in this prestigious and special project and accompany Eitan Stiva while we make Israeli history in space. This is a journey to stretch the limits of technological and human ability that redefines remote medicine, and for Kardiaxens it is proof that even the sky is not the limit."
Dr. Eran Shankar, the medical director of the Israeli Institute of Space and Aviation Medicine explains, "In space, many physiological changes occur in all body systems. The monitoring of the main life indicators using the medical watch of the Cardiacexance company allows for the first time a simple and continuous monitoring of many indicators that will help a lot in understanding the biological processes that take place in the astronauts on a space mission.
Ultrasite raised $13 million to develop an artificial intelligence system to guide cardiac ultrasound in any treatment environment
The company's innovative development, in collaboration with the Israel Institute of Space and Aviation Medicine, was chosen by the Ramon Foundation to be included in the space mission "Sky"
UltraSight, a pioneer in the field of digital health that aims to transform the field of cardiac ultrasound through artificial intelligence (AI), announced today the completion of a $13 million B funding round. The fundraising round will be used to advance several clinical development programs planned in the US. In the round participated the Yozama Korea group, the H.W. Kaufman and the Weizmann Institute of Science.
Ultrasight has developed a unique technology, based on artificial intelligence, in the field of mobile ultrasound, which enables receiving diagnostic information quickly and accurately. UltraSight offers an application interface that provides real-time guidance for the ultrasound operator, including how to grip and move the ultrasound transducer to obtain diagnostic-quality images, regardless of their skill level in ultrasound scanning. Until now, cardiac ultrasound was mostly performed by ultrasound technicians in echocardiography centers, a profession that requires long training and daily training to maintain a high level of professionalism. Ultrasight's solution actually allows medical staff without sonography training to conduct cardiac ultrasound examinations using portable ultrasound devices in any therapeutic environment and allow more patients to receive an accurate diagnosis and appropriate and fast treatment.
David Wortman, CEO of Ultrasight, said, "Ultrasight provides an innovative solution that provides an accurate response to the needs of medical teams and patients alike. The current recruitment round will allow us to become a significant player in the global ultrasound market."
The company also announced that its innovative development, in collaboration with the Israeli Institute of Space and Aviation Medicine, was chosen by the Ramon Foundation to be included in the "Rakia" space mission. As part of the mission, businessman Col. Mil. Eitan Stiva will test Ultrasight's technology on the International Space Station in order to test the applicability of conducting the test in space missions by untrained staff in the space environment. The success of the experiment may provide significant and essential medical information for the field of space medicine, since a prolonged stay in the space environment poses a significant risk to the heart and respiratory system, especially in long-term space missions far from Earth.
Andrew Cleland, CEO of the Fogarty Innovation Foundation, said, "We see a future where cardiac ultrasound will be available to every patient anywhere, and can be performed by anyone on the medical team. Turning the ultrasound review into a simple operation that does not require training and experience is an essential step in the effort to provide fast and efficient treatment to patients anywhere and at any time, regardless of their proximity to an advanced treatment center."
Montfort The Israeli will monitor Eitan Stiva's brain in a sky mission
The Israeli startup company Brain Monitor Montfort (Mon4T), which checks brain function remotely with the help of a smartphone, has been chosen to be one of the 44 Israeli companies that will compete for a place in the "sky", the Ax1 space mission of the company Axiom Space in which Eitan Stiva, the second Israeli astronaut, will participate . The Rakei mission is led by the Ramon Foundation and the Space Agency in the Ministry of Science and Technology.
As part of a 200-hour stay on the International Space Station, Eitan Stiva will perform scientific experiments and technological demonstrations in space conditions of pre-selected Israeli companies and organizations.
The Montfort company has developed an application that allows monitoring neurological symptoms such as tremors, reaction time and memory, in real time and remotely. Monfort's solution, approved by the FDA, uses the sensors present in every smartphone device and artificial intelligence (AI) to conduct neurological tests for patients with diseases such as Parkinson's, Huntington's, psychiatric diseases (such as schizophrenia) and more. This time, the application will help doctors on Earth to monitor the normal functioning of the astronauts staying in space.
The company offers to perform motor and cognitive tests during the stay on the space station. The astronauts will perform the tests themselves and easily, using the app, and the results will be sent to Earth in real time, so that the doctors can examine them, monitor and analyze the function of those staying in space against the values measured on Earth. In this way, it will be possible to examine another aspect of the stay of humans in space, and to get a picture of the motor and cognitive abilities of the participants in the mission.
The "Sky" mission is a joint initiative of the Aerospace Industry and the Ramon Foundation in preparation for a space mission that will be launched in early 2022, in which Eitan Stiva will cross the atmosphere with 2 other astronauts, as the second Israeli astronaut. The Israeli part of the mission is a rare opportunity for researchers and entrepreneurs from a variety of fields to conduct experiments in space and use the infrastructure of the International Space Station.
According to Dr. Ziv Yekuthiali, co-founder and CEO of Monfort: "The space mission is a fascinating opportunity for us to contribute to brain research in everything related to improving functions under different conditions. It is a great honor to be part of the Israeli technologies recommended for testing on the space station. We believe that the technology we developed to remotely examine patients on Earth, thus making advanced medicine accessible to them, can also help maintain the health and safety of the crew members, and their ability to perform complex tasks in space."
The experiments and technologies were selected by an independent scientific committee headed by Inbal Kreis, Israel's senior space woman, director of innovation in the systems and space division of the aerospace industry. The committee includes senior representatives from the Israel Space Agency, the Ministry of Science and Technology, the Innovation Authority, the Ministry of Health, and the leading academic institutions in Israel. The committee examined the proposals submitted based on their research potential and commercial impact, and chose the ideas that would bring with them the most significant contribution to the development of the civilian space industry and Israeli space research.
The experiments will be sent to the International Space Station subject to obtaining funding for the experiment, meeting the mission schedule, and subject to NASA approval. The Israel Space Agency in the Ministry of Science and Technology will issue a call for funding for the experiments, and the Ramon Foundation will also assist in finding alternative funding sources.
More of the topic in Hayadan:
